Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(45,851) | $(45,431) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 364 | 404 |
| Stock-based compensation expense | 5,693 | 4,760 |
| Amortization of right-of-use assets | 540 | 539 |
| Accretion of discounts on short-term investments, net | (848) | (598) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and unbilled receivable | 591 | (484) |
| Prepaid expenses and other current assets | 557 | (452) |
| Other assets | (480) | 1,210 |
| Accounts payable and accrued liabilities | 2,202 | 2,985 |
| Operating lease liabilities | (691) | (626) |
| Net cash used in operating activities | (37,923) | (37,693) |
| Investing activities | ||
| Capital expenditures | (44) | (80) |
| Maturities of short-term investments | 71,111 | 27,106 |
| Purchases of short-term investments | (71,860) | (23,563) |
| Sales of short-term investments | 2,135 | 10,265 |
| Net cash provided by investing activities | 1,342 | 13,728 |
| Financing activities | ||
| Proceeds from sales of common stock, net of expenses of $0 and $3,286, respectively | — | 53,407 |
| Proceeds from exercise of warrants, net of expense of $169 and $0, respectively | 2,088 | — |
| Proceeds from exercise of options | 493 | 373 |
| Net cash provided by financing activities | 2,581 | 53,780 |
| Net change in cash and cash equivalents | (34,000) | 29,815 |
| Cash and cash equivalents—Beginning of year | 51,470 | 21,655 |
| Cash and cash equivalents—End of year | $17,470 | $51,470 |
| Supplementary disclosure of cash flow activity: | ||
| Supplemental disclosure of non-cash investing activities: | ||
| Cash paid for taxes | $1 | $1 |
| Purchases of unsettled short-term investments included in accrued liabilities | $744 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.